Radioligands
- Catalog -

Chelatec — 2026

Table of contents

Table of contents

2-Iodomelatonin [^{125}I]



Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.25 mCi/mL

RCP: ≥ 95 %

Reference: RL05 **[^{125}I]-Iodomelatonin**

2,5-Dimethoxy-4-iodoamphetamine [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %



Reference: RL06 **[^{125}I]-(±)DOI**

AB-MECA [^{125}I]



Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 90 %

Reference: RL24 **[^{125}I]-AB-MECA**

Aminopotentidine [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %



Reference: RL15 **[^{125}I]-Aminopotentidine**

(Sar[1], Ile[8])-Angiotensin II [^{125}I]

Sequence:
Sar-Arg-Val-Tyr[^{125}I]-Ile-His-Pro-Ile-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Reference: RL21 **[^{125}I]-Sar Ile AT II**

Anti-IgE [^{125}I]

Specific Activity: 1350-2250 Ci/mmol
50-83.3 TBq/mmol

Concentration: 0.001 mCi/mL

RCP: ≥ 95 %

Reference: RL35 **[^{125}I]-Anti-IgE**

Apamin [^{125}I]

Sequence :
Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 85 %

Reference: RL50 **[^{125}I]-Apamin**

[Glp[65], Nle[75], Tyr[77]] Apelin 13 [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Sequence:
Glp-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-[^{125}I]Tyr-OH

Reference: RL64 **[^{125}I]- [Glp[65], Nle[75], Tyr[77]] Apelin 13**

Bombesin (6-14) [^{125}I]

Sequence:
H-D-Tyr[^{125}I]-Gln-Trp-Ala-Val-bAla-His-Phe-Nle-NH_2

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Reference: RL53 **[^{125}I]-BOMBESIN (6-14)**

(Tyr^8)-Bombesin [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90 %

Sequence:
Pyr-Gln-Arg-Tyr[^{125}I]-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH_2

Reference: RL23 **[^{125}I]-Tyr^8-Bombesin**

α-Bungarotoxin [^{125}I]

Sequence:
H-Ile-Val-Cys3-His-Thr-Thr-Ala-Thr-Ser-Pro-Ile-Ser-Ala-Val-Thr-Cys16-Pro-Pro-Gly-Glu-Asn-Leu-Cys23-Tyr-Arg-Lys-Met-Trp-Cys29-Asp-Ala-Phe-Cys33-Ser-Ser-Arg-Gly-Lys-Val-Val-Glu-Leu-Gly-Cys44-Ala-Ala-Thr-Cys48-Pro-Ser-Lys-Lys-Pro-Tyr-Glu-Glu-Val-Thr-Cys59-Cys60-Ser-Thr-Asp-Lys-Cys65-Asn-Pro-His-Pro-Lys-Gln-Arg-Pro-Gly

Specific Activity: 1270-1760 Ci/mmol
47-65 TBq/mmol

Concentration: 0.25 mCi/mL

RCP: ≥ 85 %

Reference: RL17 **[^{125}I]-α-Bungarotoxin**

α-CGRP [^{125}I]

(Human)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90 %

Sequence:
H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His[^{125}I]-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH_2

Reference: RL12 **[^{125}I]-α-CGRP**

Cholecystokinin Octapeptide (sulfated) [^{125}I-SIB]

Sequence:
[^{125}I-SIB]-NH-Asp-Tyr(SO_3H)-Met-Gly-Trp-Met-Asp-Phe-NH_2

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Reference: RL04 **[^{125}I]-CCK8**

α-Dendrotoxin [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 85 %

Sequence :
Gln-Pro-Arg-Arg-Lys-Leu-Cys-Ile-Leu-His-Arg-Asn-Pro-Gly-Arg-Cys-Tyr[^{125}I]-Asp-Lys-Ile-Pro-Ala-Phe-Tyr[^{125}I]-Tyr[^{125}I]-Asn-Gln-Lys-Lys-Lys-Gln-Cys-Glu-Arg-Phe-Asp-Trp-Ser-Gly-Cys-Gly-Gly-Asn-Ser-Asn-Arg-Phe-Lys-Thr-Ile-Glu-Glu-Cys-Arg-Arg-Thr-Cys-Ile-Gly-OH

Reference: RL48 **[^{125}I]-AlphaDendrotoxin**

Echistatin [^{125}I-SIB]

Sequence :
H-Glu-Cys-Glu-Ser-Gly-Pro-Cys-Cys-Arg-Asn-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Ile-Cys-Lys-Arg-Ala-Arg-Gly-Asp-Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Cys-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH (Disulfide bonds between Cys^{2} and Cys^{11}/Cys^{7} and Cys^{32}/Cys^{8} and Cys^{37}/Cys^{20} and Cys^{39})

Specific Activity: 80-95 Ci/mmol
3.0-3.5 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Reference: RL40 **[^{125}I]-Echistatin**

Endothelin-1 [^{125}I]

(Human, bovine, dog, mouse, porcine, rat)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 85 %

Sequence:
H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-[^{125}I]Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH

Reference: RL08 **[^{125}I]-Endothelin-1**

Fractalkine [^{125}I]

Sequence:
QHHGVTKCNITCSKMTSKIPVALLIHYQQ
NQASCGKRAIILETRQHRLFCADPKEQW
VKDAMQHLDRQAAALTRNG-[^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95 %

Reference: RL57 **[^{125}I]-Fractalkine**

FSH [^{125}I]
(Recombinant Human)

Specific Activity: 750 Ci/mmol
27.7 TBq/mmol

Concentration: 0.25 mCi/mL

RCP: ≥ 90 %

Sequence: [^{125}I]-
Sub-unit alpha : APDVQDCPECTLQENPFFSQPGAPI
LQCMGCCFSRAY[^{125}I]PTPLRSKKTMLVQKNVTSES
TCCVAKSY[^{125}I]NRVTVMGGFKVENHTACHCSTCY
[^{125}I]Y[^{125}I]HKS
Sub-unit beta : NSCELTNITIAIEKEECRFCISINTTWC
AGY[^{125}I]CY[^{125}I]TRDLVY[^{125}I]KDPARPKIQKTCTFKEL
VY[^{125}I]ETVRVPGCAHHADSLY[^{125}I]TY[^{125}I]PVATQCH
CGKCDSDSTDCTVRGLGPSY[^{125}I]CSFGEMKE

Reference: RL61 **[^{125}I]-FSH**

Galanine [^{125}I] (Human)

Sequence:
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-[^{125}I]Tyr-
Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-
Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-
Ser-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95 %

Reference: RL18 **[^{125}I]-Galanin (Human)**

Galanine [^{125}I] (Porcine)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95 %

Sequence:
H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-
Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-
Asn-His-Arg-Ser-Phe-His-Asp-Lys-[^{125}I]-
Tyr-Gly-Leu-Ala-NH2

Reference: RL20 **[^{125}I]-Galanin (Porcine)**

Ghrelin [^{125}I]
(Human)

Sequence :
H-Gly-Ser-Ser(octanoyl)-Phe-Leu-Ser-Pro-Glu-[^{125}I]His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95 %

Reference: RL33 **[^{125}I]-Ghrelin**

GIP [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 90 %

Sequence :
[^{125}I]Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-[^{125}I]Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-OH

Reference: RL60 **[^{125}I]-GIP**

GLP-1 (7-36) [^{125}I]

Sequence:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-[^{125}I]Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH_2

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90 %

Reference: RL58 **[^{125}I]-GLP-1 (7-36)**

Glucagon [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95 %

Sequence :
H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-[^{125}I]Tyr10-Ser-Lys-[^{125}I]Tyr13-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-NH2

Reference: RL52 **[^{125}I]-Glucagon**

Hongotoxin [^{125}I]

Sequence:
TVIDVKCTSPKQCLPPCKYQFGIRAGAK
CMNGKCKCFPH[^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 85 %

Reference: RL59 **[^{125}I]-HgTX1-A19Y/Y37F**

Interleukin-8 [^{125}I]

(Recombinant Human CXCL8)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Sequence:
AVLPRSAKEL-RCQCIKTYSK-PFHPKFIKEL-
RVIESGPHCA-NTEIIVKLSD-
GRELCLDPKENWVQRVVEKF-LKRAENS-[^{125}I]

Reference: RL16 **[^{125}I]-Interleukin-8**

Iodo-(±)-cyanopindolol [^{125}I]



Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.17 mCi/mL

RCP: ≥ 85 %

Reference: RL02 **[^{125}I]-(±)CYP**

(Phe^{13},Tyr^{19})-MCH [^{125}I]

(Recombinant Human)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95 %

Sequence:
H-Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-
Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-
Gln-Tyr-OH

Reference: RL28 **[^{125}I]-MCH**

MIBG [^{125}I]



Specific Activity: 17.5-2 20 Ci/mmol
0.6-0.7 TBq/mmol

Concentration: 0.2 mCi/mL

RCP: ≥ 95 %

Reference: RL45 **[^{125}I]-MIBG**

[Leu^{13}]Motilin [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 85 %

Sequence:
Phe-Val-Pro-Ile-Phe-Thr-[^{125}I]Tyr-Gly-Glu-Leu-Gln-Arg-Leu-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln

Reference: RL49 **[^{125}I]-Motilin**

(Nle^{4},D-Phe^{7})-α-MSH [^{125}I]

Sequence:
Ac-Ser-[^{125}I]Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH_2

Specific Activity: 2 200 Ci/mmol
81.4TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90 %

Reference: RL11 **[^{125}I]-(NDP)alpha-MSH**

Neurokinin A [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 90 %

Sequence:
[^{125}I]His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH_2

Reference: RL22 **[^{125}I]-Neurokinin A**

Neurokinin B [^{125}I]

Sequence:
Asp-Met-[^{125}I]His-Asp-Phe-Phe-MePhe-Gly-Leu-Met-NH2

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90 %

Reference: RL62 **[^{125}I]-Neurokinin B**

Neuromedin U8 [^{125}I]
(Pig)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Sequence:
Tyr[^{125}I]-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH_2

Reference: RL47 **[^{125}I]-Neuromedin U8**

Neurotensin [^{125}I]

Sequence:
Pyr-Leu-Tyr[^{125}I]-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 85 %

Reference: RL19 **[^{125}I]-Neurotensin**

Orexin A [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Sequence:
Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr[^{125}I]-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH_2

Reference: RL31 **[^{125}I]-Orexin A**

PACAP 1-27 [^{125}I]

(human, mouse, ovine, porcine, rat)

Sequence:
H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-[^{125}I]Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.025 mCi/mL

RCP: ≥ 90 %

Reference: RL09 **[^{125}I]-PACAP**

PDGF α BB [^{125}I]-SIB

Specific Activity: 480-1940 Ci/mmol
17.8-71.8 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Sequence:
SLGSLTIAEP AMIAEC**K**TRT EVFEISRRLI DRTNANFLVW PPCVEVQRCS GCCNNRNVQC RPTQVQLRPV QVR**K**IEIVR**KK**PIF**KK**ATVT LEDHLAC**K**CE TVAAARPVT-**[^{125}I-SIB]**

Reference: RL14 **[^{125}I]-SIB- PDGF α BB**

Peptide YY [^{125}I]

Sequence:
H-Tyr[^{125}I]-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr[^{125}I]-Tyr[^{125}I]-Ala-Ser-Leu-Arg-His-Tyr[^{125}I]-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr[^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.04 mCi/mL

RCP: ≥ 85 %

Reference: RL10 **[^{125}I]-Peptide YY**

---

rPTH Amide [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90 %

Sequence:
Ala-Val-Ser-Glu-Ile-Gln-Leu-Nle8-His-Asn-Leu-Gly-Lys-His-Leu-Ala-Ser-Val-Glu-Arg-Nle21-Gln-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-[^{125}I]Tyr34-NH2

Reference: RL55 **[^{125}I]-rPTH AMIDE**

[Tyr]^{0} Sauvagine [^{125}I]

Sequence:
[^{125}I]-Tyr-Glu-Gly-Pro-Pro-Ile Ser-Ile-Asp-Leu-Ser-Leu-Glu-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH2

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90 %

Reference: RL27 **[^{125}I]-Sauvagine**

SDF-1α [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.050 mCi/mL

RCP: ≥ 90 %

Sequence:
KPVSLSYRCP CRFFESHVAR ANVKHLKILN TPNCALQIVA RLKNNNRQVC IDPKLKWIQE YLEKALNK

Reference: RL29 **[^{125}I]-SDF-1α**

(Tyr^{11})-Somatostatin-14 [^{125}I]

Sequence:
H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr[^{125}I]-Thr-Ser-Cys-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Reference: RL13 **[^{125}I]- (Tyr^{11})-Somatostatin-14**

(Leu^{8},D-Trp^{22},Tyr^{25})-Somatostatin-28 [^{125}I]

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95 %

Sequence:
H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr-Thr-Ser-Cys-OH

Reference: RL38 **[^{125}I]-SST28**

Substance P [^{125}I]

Sequence:
H-Arg-Pro-[^{125}I]-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH_2

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 90 %

Reference: RL30 **[^{125}I]-Substance P Lys3**

TNF-α [^{125}I]
(Recombinant Human)

Specific Activity: 500 Ci/mmol
18.5 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 85 %

Sequence:
VRSSSRTPSD-KPVAHVVANP-QAEGQLQWLN-RRANALLANG-VELRDNQLVV-PSEGLYLIYS-QVLFKGQGCP-STHVLLTHTI-SRIAVSYQTK-VNLLSAIKSP-CQRETPEGAE-AKPWYEPIYL-GGVFQLEKGD-RLSAEINRPD
-YLDFAESGQV-YFGIIAL[^{125}I]

Reference: RL07 **[^{125}I]-TNF alpha**

Urotensin II [^{125}I]
(Human)

Sequence:
H-Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-Tyr[^{125}I]-Cys-Val-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.07 mCi/mL

RCP: ≥ 95 %

Reference: RL26 **[^{125}I]-Urotensin II**

Vasoactive Intestinal Polypeptide [^{125}I]
(Human, mouse, rat)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95 %

Sequence:
H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr[^{125}I]-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr[^{125}I]-Leu-Asn-Ser-Ile-Leu-Asn-NH_2

Reference: RL03 **[^{125}I]-VIP**

[Arg^{8}]Vasopressin [^{125}I]

Sequence:
Cys-[^{125}I]Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2

Specific Activity:	2 200 Ci/mmol 81.4 TBq/mmol
Concentration:	0.05 mCi/mL
RCP:	≥ 85 %

Reference: RL63 **[^{125}I]-Vasopressin**

Custom [^{125}I] Radioiodination

Radioiodination of proteins and peptides may be performed by different methods, namely by targeting an iodine-accepting group on the protein or by the conjugation of a small radioiodinated molecule on terminal amino groups.

Direct radioiodination

Iodogen ®, **Chloramine-T** or **Lactoperoxidase** lead to the *in situ* preparation of an electrophilic radioiodine species, which reacts with tyrosine groups.

Indirect radioiodination (conjugation method)

This labelling method provides an alternative way to introduce radioiodine into proteins using a prosthetic group labelled at high specific.

➢ Bolton Hunter's method is the most well known procedure.

➢ The *N-succinimidyl*-3-trimethylstannylbenzoate is also used, as it is more stable to *in vivo* dehalogenation.

Our experienced radiochemists will provide a tailored and collaborative service, adapted to your specific needs. Our products are delivered with a comprehensive certificate of analysis comprising:

-Radiochemical purity
-Specific activity
-Total amount of activity
-Radio HPLC

RELIABLE

PARTNER FOR RELIABLE MOLECULES

Chelatec

www.chelatec.com

CHELATEC S.A.S. I 1 rue Aronnax I 44821 SAINT HERBLAIN CEDEX I FRANCE